Emily Warmington, Gabrielle Smith, Vasileios Chortis, Raimunde Liang, Juliane Lippert, Sonja Steinhauer, Laura-Sophie Landwehr, Constanze Hantel, Katja Kiseljak-Vassiliades, Margaret E Wierman, Barbara Altieri, Paul A Foster, Cristina L Ronchi
Adrenocortical carcinoma (ACC) is an aggressive malignancy with limited treatment options. Polo-like kinase 1 (PLK1) is a promising drug target; PLK1 inhibitors (PLK1i) have been investigated in solid cancers and are more effective in TP53-mutated cases. We evaluated PLK1 expression in ACC samples and the efficacy of two PLK1i in ACC cell lines with different genetic backgrounds. PLK1 protein expression was investigated by immunohistochemistry in tissue samples and correlated with clinical data. The efficacy of Rigosertib (RGS), targeting RAS/PI3K, CDKs and PLKs, and Poloxin (Pol), specifically targeting the PLK1 polo-box domain, was tested in TP53-mutated NCI-H295R, MUC-1, and CU-ACC2 cells and in TP53-wild-type CU-ACC1...
November 1, 2023: Endocrine Connections